Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
نویسندگان
چکیده
BACKGROUND Premature clopidogrel discontinuation after drug-eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health care systems such as the Veterans Affairs (VA). METHODS AND RESULTS We evaluated the frequency of premature clopidogrel discontinuation, defined as a gap between clopidogrel refills of ≥90 days during the first 6 months of treatment, among 12 707 patients who received drug-eluting stents in VA hospitals between 2008 and 2010. We evaluated the association between premature discontinuation and all-cause mortality and/or acute myocardial infarction, variation in the proportion of premature discontinuation among hospitals, the patient and hospital characteristics associated with premature discontinuation, and the extent to which unexplained hospital characteristics contribute to premature discontinuation. Of the patients, 963 (7.6%) discontinued clopidogrel prematurely. Premature discontinuation was associated with acute myocardial infarction and all-cause mortality (hazard ratio 1.65, 95% CI 1.37-1.99, P<0.001). The proportion of patients with premature discontinuation varied across hospitals from 0% to 16.5% (P<0.001). We found a median of 24% greater odds of patients with identical covariates with premature discontinuation at one randomly selected hospital compared with another (median odds ratio 1.24, 95% CI 1.17-1.44). Patient factors associated with premature discontinuation included lack of cardiology follow-up within 30 days of discharge and smaller initial clopidogrel fill. CONCLUSION One in 13 patients prematurely discontinued clopidogrel, and variation in discontinuation across hospitals was observed. Patient factors were associated with premature discontinuation that may represent targets for quality improvement.
منابع مشابه
Clopidogrel desensitization after drug-eluting stent placement.
OBJECTIVES We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective. BACKGROUND Adverse reactions to clopidogrel are not uncommon, and affected patients must switch to ticlopidine after drug-eluting stent placement, despite its more malignant side-effect profile, because of the risk of ischemic events associated with premature discontinua...
متن کاملProlonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
BACKGROUND Current guidelines recommend combining clopidogrel with aspirin for up to 1 year after coronary stenting, but the value of clopidogrel beyond this time is uncertain. METHODS AND RESULTS We evaluated all patients in the Veterans Administration healthcare system receiving either drug-eluting or bare metal stents from 2002 to 2006. The Veterans Administration National Patient Care and...
متن کاملPrevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents
Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. This advisory stresses the importance of 12 months of dual antiplatelet therapy after...
متن کاملEpistaxis as the reason for premature discontinuation of clopidogrel after percutaneous coronary angioplasty with stent implantation.
BACKGROUND Haemorrhagic complications, including epistaxis, are the main reason for discontinuation of antiplatelet therapy in patients after stent implantation which increases risk of in-stent thrombosis. AIM To evaluate the incidence of bleeding complications leading to premature discontinuation of antiplatelet therapy in patients after percutaneous coronary intervention (PCI) with stent im...
متن کاملClopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel
BACKGROUND Incidence and predictors of clopidogrel discontinuation after drug eluting stent (DES) implantation, in real world practice, are poorly known. METHODS Prospective study included all patients who underwent implantation of at least one DES between February 2006 and January 2007. Predictors of clopidogrel discontinuation were assessed by a multivariable analysis. RESULTS In 269 pati...
متن کامل